Sun Pharma: FDA Approves YONSA For Prostate Cancer Treatment

(RTTNews) - India-based Sun Pharmaceutical Industries Ltd. and Churchill Pharmaceuticals, LLC. announced Wednesday the approval by U.S. Food and Drug Administration or FDA for YONSA (abiraterone acetate) tablets in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer or mCRPC.

YONSA is a CYP17 inhibitor which uses proprietary SoluMatrix Fine Particle Technology to create a micronized (smaller particle size) formulation of abiraterone acetate tablets.

The company noted that YONSA was shown in clinical studies to be an effective form of abiraterone acetate, and can be taken with or without food, in combination with methylprednisolone.

YONSA in combination with methylprednisolone was filed as a New Drug Application and will be promoted as a branded product in the U.S.

Sun Pharma had acquired YONSA from Churchill Pharma and will commercialize the drug in the U.S. Churchill is eligible to receive upfront and sales-linked milestone payments, and royalties on sales from Sun Pharma.